Conflict of interest statement: S Berentsen has received research support from 
Mundipharma, travel support from Alexion and Apellis, lecture honoraria from 
Alexion, Bioverativ, and Janssen-Cilag, and has consulted for Apellis, 
Bioverativ, Momenta Pharmaceuticals, and True North Therapeutics, outside the 
submitted work. A Röth has received research support from Alexion and Roche, 
travel support from Alexion and AbbVie, lecture honoraria from Alexion, Roche, 
and Novartis, and has consulted for Alexion, Bioverativ, Novartis, and True 
North Therapeutics, outside the submitted work. U Randen reports no conflicts of 
interest. B Jilma has received reimbursement for travel for presentations and 
scientific advice from True North Therapeutics (a Bioverativ Company), outside 
the submitted work. GE Tjønnfjord has received research support from 
Mundipharma, Janssen-Cilag and Alexion Pharma, and lecture honoraria from 
Janssen-Cilag, Alexion Pharma, and Roche Pharma, outside the submitted work.